Top stories in endocrinology: Novel insulin pump system reduces hypoglycemia, hormone therapy increases breast cancer risk in transgender women

Among the top stories in endocrinology last week were a study that found adults with long-standing type 1 diabetes and hypoglycemia unawareness using an insulin pump therapy system with an algorithm-driven, insulin-suspension feature experienced fewer hypoglycemic events than those using sensor-augmented pump therapy and research that determined transgender women prescribed gender-affirming hormone therapy had a 47-fold higher risk for developing breast cancer during a median of 18 years than did cisgender men.

Other highlights included the exploration of a monoclonal antibody as a disease-modifying therapy for type 1 diabetes, a study that found abnormal sleep patterns raised HbA1c levels in prediabetes and untreated type 2 diabetes and a study that determined the aromatase inhibitor anastrozole effectively slowed bone age advancement in children with congenital adrenal hyperplasia during 5 years of treatment without changes in bone mineral density or body composition.

‘Suspend-before-low’ feature reduces hypoglycemia with pump therapy in type 1 diabetes

Adults with long-standing type 1 diabetes and hypoglycemia unawareness using an insulin pump therapy system with an algorithm-driven, insulin-suspension feature experienced fewer hypoglycemic events than those using sensor-augmented pump therapy, according to findings published in The Lancet Diabetes & Endocrinology. Read more.

Hormone therapy increases breast cancer risk among transgender women

Transgender women prescribed gender-affirming hormone therapy have a 47-fold higher risk for developing breast cancer during a median of 18 years vs. cisgender men, although this observed risk remained lower than that for cisgender women, according to findings published in The BMJ. Read more.

Monoclonal antibody explored as disease-modifying therapy for type 1 diabetes

GeNeuro announced positive phase 2a trial results for temelimab, a monoclonal antibody that targets a protein implicated in the onset and development of type 1 diabetes, making the drug a potential disease-modifying therapy for the condition, according to a press release from the company. Read more.

Abnormal sleep patterns raise HbA1c levels in prediabetes, untreated type 2 diabetes

Adults with prediabetes or untreated type 2 diabetes who sleep fewer than 5 hours or more than 8 hours per night tend to have higher blood glucose levels than those who sleep between 7 and 8 hours, according to findings published in Diabetes Care. Read more.

Aromatase inhibitor therapy slows bone age advancement in congenital adrenal hyperplasia

The aromatase inhibitor anastrozole effectively slowed bone age advancement in children with congenital adrenal hyperplasia during 5 years of treatment without changes in bone mineral density or body composition, suggesting the therapy could serve as a useful add-on therapy to glucocorticoid replacement, according to findings published in Clinical Endocrinology. Read more.